Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report

Keyphrases

• Combination Chemotherapy 100%
• Brentuximab Vedotin 100%
• Gray Zone Lymphoma 100%
• Liver Impairment 100%
• Diffuse Large B-cell Lymphoma (DLBCL) 20%
• Chemotherapy 20%
• Predictive Biomarker 20%
• Targeted Therapy 20%
• Lymphoma Subtype 20%
• Cytotoxic Chemotherapy 20%
• Classic Hodgkin Lymphoma 20%
• NF-κB Signaling 20%
• Improved Outcomes 10%
• Molecular Mechanism 10%
• Treatment Response 10%
• Diagnostic Challenge 10%
• Molecular Pathogenesis 10%
• Near-complete 10%
• Young Males 10%
• Complete Resolution 10%
• Lymphoma 10%
• Cyclophosphamide 10%
• Follow-up Examination 10%
• Adjusted Dose 10%
• Monotherapy 10%
• Complete Response 10%
• Patient-completed 10%
• Accurate Diagnosis 10%
• Etoposide 10%
• Molecular Analysis 10%
• Immunoblot Analysis 10%
• Recurrent Disease 10%
• Prednisone 10%
• Optimal Treatment 10%
• Poor Performance Status 10%
• Lymphoma Patients 10%
• Histopathological Examination 10%
• Doxorubicin 10%
• Lymphadenopathy 10%
• Enzyme Level 10%
• Bilirubin Level 10%
• Liver Enzymes 10%
• CD30 10%
• Hepatosplenomegaly 10%
• Evaluation Analysis 10%
• TP53 Expression 10%
• Apoptosis Regulation 10%
• Overlapping Features 10%
• Organ Impairment 10%
• CD30 Positive 10%
• Repeat Imaging 10%
• End Organ Failure 10%
• TNFR Superfamily 10%
• Full-time Work 10%
• Performance Baseline 10%

Medicine and Dentistry

• Combination Chemotherapy 100%
• Severe Hepatic Impairment 100%
• Brentuximab Vedotin 100%
• Diffuse Large B-Cell Lymphoma 40%
• Biological Marker 40%
• Targeted Therapy 40%
• Cytotoxic Chemotherapy 40%
• Classical Hodgkin Lymphoma 40%
• Recurrent Disease 20%
• Monotherapy 20%
• Diagnosis 20%
• Programmed Cell Death 20%
• Treatment Response 20%
• Molecular Pathology 20%
• Cyclophosphamide 20%
• Etoposide 20%
• Prednisone 20%
• Lymphadenopathy 20%
• Doxorubicin 20%
• Bilirubin 20%
• Liver Enzyme 20%
• Immunophenotyping 20%
• Hepatosplenomegaly 20%